<DOC>
	<DOCNO>NCT02847637</DOCNO>
	<brief_summary>This randomize , multicenter , open-label , Phase 3 clinical study participant age 12 year old evaluate efficacy , safety , pharmacokinetics prophylactic emicizumab versus prophylaxis participant severe hemophilia A without inhibitor FVIII .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Efficacy , Safety , Pharmacokinetics Prophylactic Emicizumab Versus Prophylaxis Hemophilia A Participants Without Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Body weight &gt; =40 kilogram ( kg ) time screen Diagnosis severe congenital hemophilia A Documentation detail prophylactic episodic FVIII treatment number bleed episode least last 24 week Adequate hematologic function Adequate hepatic function Adequate renal function For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method result failure rate &lt; 1 % per year treatment period least 5 elimination halflives ( 24 week ) last dose study drug Inherited acquire bleed disorder hemophilia A Previous current treatment thromboembolic disease sign thromboembolic disease Conditions may increase risk bleed thrombosis History clinically significant hypersensitivity associate monoclonal antibody therapy component emicizumab injection Known human immunodeficiency virus ( HIV ) infection CD4 count &lt; 200 cells/mcL within 24 week prior screen . Participants HIV infection CD4 &gt; 200 meet criterion eligible Use systemic immunomodulators enrollment plan use study , exception antiretroviral therapy Concurrent disease , treatment , abnormality clinical laboratory test could interfere conduct study , may pose additional risk , would , opinion investigator , preclude participant 's safe participation completion study Planned surgery ( exclude minor procedure ) study Receipt emicizumab prior investigational study ; investigational drug treat reduce risk hemophilic bleeds within 5 halflives last drug administration ; nonhemophiliarelated investigational drug concurrently , within last 30 day 5 halflives , whichever short Pregnant lactating , intend become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Emicizumab</keyword>
</DOC>